文献速递肾小球疾病

NELL1 是恶性肿瘤相关膜性肾病的靶抗原

NELL1 is a target antigen in malignancy-associated membranous nephropathy.
PubMed 文献 · Kidney Int · 2020-08-20

该研究用质谱技术从冷冻肾活检组织中洗脱免疫复合物以探索恶性肿瘤相关膜性肾病的靶抗原,发现 NELL1 免疫复合物独特存在于部分膜性肾病活检组织中,NELL1 阳性病例呈节段至不完整 IgG 毛细血管袢染色和 IgG1 优势沉积,且并发恶性肿瘤比例高于 PLA2R 和 THSD7A 阳性病例。

要点

  • NELL1 是恶性肿瘤相关膜性肾病的新靶抗原。
  • NELL1 阳性者多为节段至不完整 IgG 染色且 IgG1 优势。
  • NELL1 相关膜性肾病并发恶性肿瘤比例高于其他已知类型。

核心结论

  • NELL1 相关膜性肾病具有不完整毛细血管袢染色和 IgG1 优势的独特组织病理学,且较其他已知类型更常与恶性肿瘤相关。

研究设计与样本

  • 利用质谱法在恶性肿瘤相关膜性肾病的冷冻肾活检组织中探索抗原,比较未知与已知类型膜性肾病病例。
  • 通过免疫荧光后续识别 NELL1 阳性病例,并在连续系列中分析其比例。

主要发现

  • 质谱分析显示 NELL1 免疫复合物独特存在于膜性肾病活检组织中。
  • 连续系列中 3.8% 的 PLA2R 和 THSD7A 阴性病例为 NELL1 阳性。
  • NELL1 阳性病例中 93.4% 呈节段至不完整 IgG 毛细血管袢染色,95.5% 呈优势或共优势 IgG1 亚类染色。
  • NELL1 阳性膜性肾病患者平均年龄 66.8 岁,男性略多(58.2%),33% 并发恶性肿瘤。
  • 与 PLA2R 和 THSD7A 阳性病例相比,NELL1 相关组恶性肿瘤比例更高。

临床怎么用

  • 对 PLA2R 和 THSD7A 阴性的膜性肾病患者可考虑检测 NELL1 以识别恶性肿瘤相关病例。
  • NELL1 阳性膜性肾病患者应评估并发恶性肿瘤的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with membranous nephropathy have an increased risk of malignancy compared to the general population, but the target antigen for malignancy-associated membranous nephropathy is unknown. To explore this, we utilized mass spectrometry for antigen discovery in malignancy-associated membranous nephropathy examining immune complexes eluted from frozen kidney biopsy tissue using protein G bead immunoglobulin capture. Antigen discovery was performed comparing cases of membranous nephropathy of unknown and known type. Mass spectrophotometric analysis revealed that nerve epidermal growth factor-like 1 (NELL1) immune complexes were uniquely present within the biopsy tissue in membranous nephropathy. Additional NELL1-positive cases were subsequently identified by immunofluorescence. In a consecutive series, 3.8% of PLA2R- and THSD7A-negative cases were NELL1-positive. These NELL1-positive cases had segmental to incomplete IgG capillary loop staining (93.4%) and dominant or co-dominant IgG1-subclass staining (95.5%). The mean age of patients with NELL1-positive membranous nephropathy was 66.8 years, with a slight male predominance (58.2%) and 33% had concurrent malignancy. Compared with PLA2R- and THSD7A-positive cases of membranous nephropathy, there was a greater proportion of cases with malignancies in the NELL1-associated group. Thus, NELL1-associated membranous nephropathy has a unique histopathology characterized by incomplete capillary loop staining, IgG1-predominance, and is more often associated with malignancy than other known types of membranous nephropathy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 2020. PMID: 32828756. doi:10.1016/j.kint.2020.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。